The bulletin recommends that drugs to induce or maintain remission should always be started by a specialist but once remission is achieved prescribing can be continued and monitored by a GP.
The bulletin covers aminosalicylates, immunosupressants, corticosteroids and tumour necrosis factor (TNF) inhibitors. The advantages and disadvantages of each class are reviewed in the context of Crohn's disease and ulcerative colitis.
Action: Clinicians will find this bulletin a useful summary of the drug management inflammatory bowel disease.
|« Pulmicort pMDI to be discontinued||JCVI advice on the pneumococcal vaccination programme »|